Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disease defined by abnormal ventricular thickening and is most commonly associated with pathogenic variants in sarcomeric and signaling genes. Despite identification of many causal genes, a substantial fraction of patients lack detectable pathogenic variants in established HCM genes. Prior work identified RPS6KB1, a component of the AKT signaling pathway, as contributing to HCM. The present study extended genetic investigation to other members of the AKT pathway to assess whether variants in AKT1, mTOR, and RICTOR might represent additional genetic risk factors for HCM in an Indian patient cohort.
The authors performed exome sequencing on an Indian-specific cohort of patients diagnosed with HCM. The source text states that exome sequencing was used to identify rare coding variants in genes of the AKT signaling pathway. Additional cohort demographics, exact sample size, and recruitment details were not reported in the available abstract and summary.
Exome analysis uncovered six heterozygous missense variants in unrelated HCM patients. The specific variants reported were:
According to the report, these variants were either novel or ultra-rare in population databases.
The six identified variants were classified as likely pathogenic following the American College of Medical Genetics and Genomics (ACMG) guidelines. The abstract indicates the variants were novel or ultra-rare, supporting their potential clinical relevance; the source did not provide allele frequencies, detailed ACMG evidence codes, or family segregation data in the summary text.
To evaluate potential functional consequences, the investigators expressed mutant forms of AKT1, mTOR, and RICTOR and compared them with wild-type proteins in a cardiomyocyte cell model. The experimental design as described in the abstract included assessment of cellular hypertrophy measures, signaling pathway activation, hypertrophic gene expression, and global protein synthesis. Details such as the specific cardiomyocyte model (primary human, iPSC-derived, or rodent), transfection methods, time points, or quantitative assay protocols were not reported in the abstract.
All six mutant proteins produced a consistent pattern of cellular and molecular changes relative to wild-type controls in the cardiomyocyte assay. Reported effects included:
These convergent findings across different mutants led the authors to interpret the variants as producing a gain-of-function effect on the AKT/mTOR/RICTOR signaling axis.
Based on genetic identification and concordant functional data, the authors conclude that rare heterozygous missense variants in AKT1, mTOR, and RICTOR may represent genetic risk factors for HCM in the studied Indian cohort. The in vitro evidence—cell enlargement, increased mTOR pathway signaling, hypertrophic gene induction, and elevated protein synthesis—supports a mechanism whereby these variants enhance pathway activity and promote hypertrophic remodeling. The manuscript positions these findings in the context of prior evidence implicating other AKT pathway members (for example, RPS6KB1) in HCM.
The study was approved by the Institutional Ethical Committee of the Institute for Stem Cell Science and Regenerative Medicine, Bangalore. The authors declare that patient consent procedures and relevant reporting guidelines were followed. Data relevant to the study are available from the corresponding author upon reasonable request, and the article states that all relevant data are included in the manuscript. Funding sources listed in the report include the Department of Biotechnology (BT/PR45262/MED/12/955/2022), Anusandhan National Research Foundation (ANRF CRG/2023/004193), Indian Council for Medical Research (ICMR), IFCPAR/CEFIPRA (CSRP project no. 7003-1), and the American Heart Association.
The available abstract and summary describe genetic discovery and functional assays but do not provide detailed cohort size, segregation analyses, comprehensive ACMG evidence codes, or full experimental methods in the source text provided here. These details would be necessary to fully evaluate variant pathogenicity and clinical implications. The manuscript is a medRxiv preprint and has not undergone peer review; the authors explicitly note that the results should not yet be used to guide clinical practice.